[{"id":"4f28ce0c-9a5a-4a61-b5dd-312c3d0839fe","acronym":"KEYNOTE-A10","url":"https://clinicaltrials.gov/study/NCT03058289","created_at":"2021-01-18T15:03:51.688Z","updated_at":"2025-02-25T14:37:17.876Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","source_id_and_acronym":"NCT03058289 - KEYNOTE-A10","lead_sponsor":"Intensity Therapeutics, Inc.","biomarkers":" MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • cisplatin/vinblastine/SHAO-FA (INT230-6)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 02/22/2023","study_completion_date":" 02/22/2023","last_update_posted":"2024-08-13"},{"id":"5c81a4de-97be-4d18-8c2e-fddbafac6d68","acronym":"INVINCIBLE","url":"https://clinicaltrials.gov/study/NCT04781725","created_at":"2021-03-04T12:52:17.514Z","updated_at":"2024-07-02T16:36:20.608Z","phase":"Phase 2","brief_title":"INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer","source_id_and_acronym":"NCT04781725 - INVINCIBLE","lead_sponsor":"Ottawa Hospital Research Institute","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cisplatin/vinblastine/SHAO-FA (INT230-6)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/25/2021","start_date":" 03/25/2021","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2021-11-17"}]